*Sponsored
Market Crux Announces Coverage Mainz Biomed (NASDAQ: MYNZ)
(MYNZ) Will Be Topping Our Watchlist Starting Tomorrow
Morning—Tuesday, November 18, 2025
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
(MYNZ) Comes Backed By Several Potential Catalysts, Keep Reading To See Why We Have All Eyes On This Right Now
Don't Wait Until Morning—Pull Up (MYNZ) Tonight…
November 17, 2025
Time to Look | See Why (MYNZ) Just Landed On Tomorrow's Radar Dear Reader, Every breakthrough begins the same way. Not with a headline. Not with a fanfare. But with a handful of researchers, a stubborn problem, and a sense that "good enough" simply isn't good enough. That's the atmosphere surrounding a company I've been studying closely — one that's gaining traction for its bold approach to early cancer detection. A company working in a space where timing matters more than almost anything else. Tonight, I'm pulling back the curtain on Mainz Biomed (NASDAQ: MYNZ). And that's exactly why (MYNZ) will be topping our watchlist tomorrow morning — Tuesday, November 18, 2025. Keep something in mind: (MYNZ) has less than 6M shares available in its public float, according to MarketWatch. When floats are this small, the potential exists for big moves if demand begins to shift. With a market cap under $10M — and shares currently sitting below $2 — (MYNZ) appears to have been flying under most radars… until now. In a report issued last week, analyst Michael Okunewitch of Maxim Group reiterated his rating on (MYNZ) with a $14 target, which suggests over 900% upside potential from its recent $1.31 range. 
Mainz Biomed (NASDAQ: MYNZ) is a firm aiming to transform how colorectal cancer and advanced precancerous lesions are detected — and doing it with a level of precision, simplicity, and scientific depth that's getting serious attention across the diagnostics world. This isn't noise. It's substance. And it's unfolding right now. A Mission Built Around One Simple Idea: Catch It Earlier
Colorectal cancer is one of the most frequently diagnosed and most deadly cancers worldwide. For many, the difference between a difficult fight and a manageable outcome comes down to a single factor: Detection before it turns into something worse.
(MYNZ) has centered its mission on exactly that point. Their work is focused on tools designed to detect not just cancer… but its earliest warning signs — advanced adenomas, the precancerous lesions that often develop over time before progressing into something far more dangerous. If those lesions can be found early… everything changes. And that's where (MYNZ)'s technology begins to shine. A Flagship Test Already in Use — With Strong Satisfaction
and Accuracy
(MYNZ)'s first commercial product, ColoAlert®, is already being used across Europe. It's an at-home test designed to be: - Non-invasive
- Easy to collect
- Fast for labs to process
- Built around DNA and blood markers that indicate potential issues
The test has demonstrated strong clinical markers — including high accuracy in detecting colorectal cancer — and has earned exceptional satisfaction scores from patients who've used it. But what elevates (MYNZ) isn't the first-generation product. It's what comes next. A Next-Generation Screening Platform That's Built
to Detect Trouble Earlier Than Most
While conventional at-home screening tools look for what's already visible, (MYNZ) is developing a next-generation test that looks deeper — into molecular signals that appear long before any physical abnormalities. This platform blends: - mRNA biomarkers
- A proprietary algorithm
- FIT testing
- Advanced extraction and PCR technologies
The result is a test designed to read the earliest "signatures" that indicate a precancerous lesion is forming — often before symptoms or visual changes appear. In multiple independent clinical studies, this approach has already delivered a powerful combination of: - High sensitivity for detecting colorectal cancer
- Strong performance in identifying advanced adenomas
- Reliable specificity across tested populations
This is the kind of data that catches the attention of clinicians, researchers, and — as you'll see next — some of the largest diagnostics companies in the world. When Two Giants Show Up… You Pay Attention
Quietly — and without fanfare — (MYNZ) secured agreements with Thermo Fisher Scientific and Quest Diagnostics, two of the most influential players in global diagnostics. These are not casual collaborations. They are strategic alignments. Thermo Fisher Scientific
Thermo Fisher provides the extraction platforms, PCR systems, and technical support that will help advance (MYNZ)'s next-generation assays. During development, they are supplying equipment and consumables at significant discounts — a strong indicator of belief in the underlying technology. Quest Diagnostics
Quest — one of the largest reference labs in the United States — is now positioned as a lab partner for (MYNZ)'s pivotal U.S. studies. In addition, Quest obtained a semi-exclusive U.S. distribution option tied to regulatory milestones. When two industry heavyweights lean in like this… something is happening. And (MYNZ) hasn't stopped there. A Business Model Designed for Scale — Not Bottlenecks
Most competitors in this space depend on centralized processing. That means large, expensive facilities handling huge volumes of tests — and all the bottlenecks that come with it. (MYNZ) chose a different path. Its decentralized model allows trained labs across many regions to run the test independently. That means: - Faster adoption
- Lower infrastructure burden
- Easier scaling
- Wider geographic reach
This isn't just a scientific advantage — it's a commercial one. A structure built for speed and scale. A Pipeline Extending Into One of Medicine's Hardest Challenges
Beyond colorectal cancer, (MYNZ) is working on future applications — including a promising approach to pancreatic cancer detection. Through a partnership with a leading bio-analytics platform company, (MYNZ) is accessing next-generation biomarkers and algorithms aimed at identifying pancreatic cancer earlier through blood-based signals. Early validation has already shown strong sensitivity and specificity in analyzing these biomarkers. Pancreatic cancer is historically one of the most difficult cancers to detect early. Very few diagnostics companies even attempt to address it. (MYNZ) is stepping into that arena with data that suggests real potential. A Team With Experience Where It Counts
One of the most overlooked strengths of any diagnostics company is its people. (MYNZ)'s leadership team brings experience from global diagnostic powerhouses — including Roche, Abbott, and Qiagen. Their advisory board includes clinicians and oncology experts who have spent decades at the forefront of early detection and molecular diagnostics. This matters. Because building a high-performance screening tool isn't just about innovation. It's about execution — and the right team can make all the difference. 7 Reasons Why (MYNZ) Will Be Topping Our Watchlist Tomorrow Morning— Tuesday, November 18, 2025
1. Small Float: with fewer than 6M shares available, (MYNZ)'s small float could witness the potential for big moves if demand begins to shift. 2. Analyst Coverage: a recent report from Maxim Group assigned a $14 target for (MYNZ), a figure that suggests 900% upside potential. 3. Higher Potential For Growth: with a valuation under $10M, (MYNZ) is currently sitting in territory that many early-stage watchers monitor closely. 4. Under The Radar: while currently sitting below $2, (MYNZ) appears to be going unnoticed by much of the broader market. 5. Major Partnerships: collaborations with Thermo Fisher and Quest Diagnostics provide (MYNZ) with support from two highly recognized names in diagnostics. 6. Next-Gen Platform: strong sensitivity data from the molecular screening technology being advanced by (MYNZ) has drawn interest from those following early-stage detection advancements. 7. Scalable Model: the decentralized testing structure used by (MYNZ) allows the platform to expand without the bottlenecks common in centralized lab systems. Take A Look At (MYNZ) Before Tomorrow Morning…
As you've seen, there's a lot lining up around (MYNZ) right now — a small float under 6M shares, a valuation under $10M, and it's sitting below $2, in a range that many haven't paid attention to yet. Add in Maxim Group's $14 target, high-profile collaborations with Thermo Fisher and Quest Diagnostics, a next-generation platform producing strong sensitivity data, and a scalable model designed for broader reach… and it's no surprise (MYNZ) landed on our radar. We will have all eyes on (MYNZ) tomorrow morning. Take a look at (MYNZ) before you call it a night. Also, keep a lookout for my morning update. Have a good night. Sincerely,
Gary Silver
Managing Editor,
Market Crux | 
